Acute Pulmonary Embolism in Women: Focus on Estrogen Therapy as a Predisposing Factor

Objectives:Acute pulmonary embolism (APE) is a potentially fatal disorder. The literature shows that estrogen therapy is correlated with an increase in mortality and morbidity. Accordingly, the purpose of the present study was to investigate the prevalence and prognostic significance of recent histo...

Full description

Bibliographic Details
Main Authors: Hassan Aghajani, Amine Ghram, Yaser Jenab, Mahboobeh Aghajani, Saeed ghodsi, Azita Hajhossein Talasaz, saeed tofighi
Format: Article
Language:English
Published: Tehran University of Medical Sciences 2021-08-01
Series:Acta Medica Iranica
Subjects:
Online Access:https://acta.tums.ac.ir/index.php/acta/article/view/8441
_version_ 1819293111367499776
author Hassan Aghajani
Amine Ghram
Yaser Jenab
Mahboobeh Aghajani
Saeed ghodsi
Azita Hajhossein Talasaz
Amine Ghram
saeed tofighi
author_facet Hassan Aghajani
Amine Ghram
Yaser Jenab
Mahboobeh Aghajani
Saeed ghodsi
Azita Hajhossein Talasaz
Amine Ghram
saeed tofighi
author_sort Hassan Aghajani
collection DOAJ
description Objectives:Acute pulmonary embolism (APE) is a potentially fatal disorder. The literature shows that estrogen therapy is correlated with an increase in mortality and morbidity. Accordingly, the purpose of the present study was to investigate the prevalence and prognostic significance of recent history of estrogen therapy in women with APE. Methods: This study was conducted on female patients admitted to our hospital between January 2008 and January 2016. A total of 276 patients (mean age = 62.66 ± 08 y) with confirmed APE were divided into groups with and without recent estrogen therapy. The relationships between estrogen and clinical findings, risk factors, imaging findings, and in-hospital mortality were analyzed. Results: Among the 276 women with APE at presentation, 37 (13.4%) patients had a recent history of estrogen therapy. The estrogen group had a lower frequency of hypertension (21.6% vs49.8%; P< .001), immobilization of at least 3 days (16.2% vs 33.5%; P = .035), and pleural effusion (0% vs16.7%; P = .007) than the group without recent estrogen use. Among the 276 patients, the rate of 1 year’s mortality was 15.8% for the group without recent estrogen therapy. No death occurred in the estrogen group. Conclusion: older age, tachycardia, tachypnea, malignancy, and lack of obesity were the predictors of 1 year’s mortality. Among the patients with APE in our study, 13.4% had a history of recent estrogen therapy. No death occurred during the 1-year follow-up of these patients.
first_indexed 2024-12-24T04:05:14Z
format Article
id doaj.art-e1fb3a8ac663492889ccdcd6cf86495f
institution Directory Open Access Journal
issn 0044-6025
1735-9694
language English
last_indexed 2024-12-24T04:05:14Z
publishDate 2021-08-01
publisher Tehran University of Medical Sciences
record_format Article
series Acta Medica Iranica
spelling doaj.art-e1fb3a8ac663492889ccdcd6cf86495f2022-12-21T17:16:12ZengTehran University of Medical SciencesActa Medica Iranica0044-60251735-96942021-08-0159610.18502/acta.v59i6.6894Acute Pulmonary Embolism in Women: Focus on Estrogen Therapy as a Predisposing FactorHassan AghajaniAmine GhramYaser JenabMahboobeh AghajaniSaeed ghodsiAzita Hajhossein TalasazAmine Ghramsaeed tofighi0Tehran Heart Center, Tehran university of medical sciences, Tehran, IranObjectives:Acute pulmonary embolism (APE) is a potentially fatal disorder. The literature shows that estrogen therapy is correlated with an increase in mortality and morbidity. Accordingly, the purpose of the present study was to investigate the prevalence and prognostic significance of recent history of estrogen therapy in women with APE. Methods: This study was conducted on female patients admitted to our hospital between January 2008 and January 2016. A total of 276 patients (mean age = 62.66 ± 08 y) with confirmed APE were divided into groups with and without recent estrogen therapy. The relationships between estrogen and clinical findings, risk factors, imaging findings, and in-hospital mortality were analyzed. Results: Among the 276 women with APE at presentation, 37 (13.4%) patients had a recent history of estrogen therapy. The estrogen group had a lower frequency of hypertension (21.6% vs49.8%; P< .001), immobilization of at least 3 days (16.2% vs 33.5%; P = .035), and pleural effusion (0% vs16.7%; P = .007) than the group without recent estrogen use. Among the 276 patients, the rate of 1 year’s mortality was 15.8% for the group without recent estrogen therapy. No death occurred in the estrogen group. Conclusion: older age, tachycardia, tachypnea, malignancy, and lack of obesity were the predictors of 1 year’s mortality. Among the patients with APE in our study, 13.4% had a history of recent estrogen therapy. No death occurred during the 1-year follow-up of these patients.https://acta.tums.ac.ir/index.php/acta/article/view/8441Pulmonary embolismEstrogenMortalityThromboembolismDeep vein thrombosis
spellingShingle Hassan Aghajani
Amine Ghram
Yaser Jenab
Mahboobeh Aghajani
Saeed ghodsi
Azita Hajhossein Talasaz
Amine Ghram
saeed tofighi
Acute Pulmonary Embolism in Women: Focus on Estrogen Therapy as a Predisposing Factor
Acta Medica Iranica
Pulmonary embolism
Estrogen
Mortality
Thromboembolism
Deep vein thrombosis
title Acute Pulmonary Embolism in Women: Focus on Estrogen Therapy as a Predisposing Factor
title_full Acute Pulmonary Embolism in Women: Focus on Estrogen Therapy as a Predisposing Factor
title_fullStr Acute Pulmonary Embolism in Women: Focus on Estrogen Therapy as a Predisposing Factor
title_full_unstemmed Acute Pulmonary Embolism in Women: Focus on Estrogen Therapy as a Predisposing Factor
title_short Acute Pulmonary Embolism in Women: Focus on Estrogen Therapy as a Predisposing Factor
title_sort acute pulmonary embolism in women focus on estrogen therapy as a predisposing factor
topic Pulmonary embolism
Estrogen
Mortality
Thromboembolism
Deep vein thrombosis
url https://acta.tums.ac.ir/index.php/acta/article/view/8441
work_keys_str_mv AT hassanaghajani acutepulmonaryembolisminwomenfocusonestrogentherapyasapredisposingfactor
AT amineghram acutepulmonaryembolisminwomenfocusonestrogentherapyasapredisposingfactor
AT yaserjenab acutepulmonaryembolisminwomenfocusonestrogentherapyasapredisposingfactor
AT mahboobehaghajani acutepulmonaryembolisminwomenfocusonestrogentherapyasapredisposingfactor
AT saeedghodsi acutepulmonaryembolisminwomenfocusonestrogentherapyasapredisposingfactor
AT azitahajhosseintalasaz acutepulmonaryembolisminwomenfocusonestrogentherapyasapredisposingfactor
AT amineghram acutepulmonaryembolisminwomenfocusonestrogentherapyasapredisposingfactor
AT saeedtofighi acutepulmonaryembolisminwomenfocusonestrogentherapyasapredisposingfactor